BackAdaptimmune Therapeutics Plc Overview

Adaptimmune Therapeutics Plc EBIT

EBIT (Earnings Before Interest and Taxes) analysis for ADAP.

Quarterly EBIT

-$28.77M
↓ 143.32% YoY

As of Jun 30, 2025

Annual EBIT (TTM)

-$160.35M
↓ 80.41% YoY

Trailing 12 months ending Jun 30, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin